Why AI Models Never Say Your Brand Name: The 0% Brand Recognition Crisis in Pharma
The Most Expensive Branding Failure You Haven't Measured
Across 23 pharmaceutical brands analyzed, AI models use brand names exactly 0% of the time. Not sometimes. Not rarely. Zero percent. When patients, physicians, and caregivers ask ChatGPT, Gemini, or Perplexity about your product, the response they receive strips away the brand identity your organization has spent hundreds of millions of dollars building.
This is the defining pharma brand AI visibility crisis of 2025, and the vast majority of pharmaceutical companies have no idea it is happening.
PharmaGEO platform analysis across OpenAI, Gemini, and Perplexity reveals a consistent, structural pattern: AI models default to International Nonproprietary Names (INNs) and drug class descriptors when answering questions about pharmaceutical products. Your brand name — the asset sitting at the center of your commercial strategy — is functionally invisible in the fastest-growing information channel in healthcare.
Key Takeaway: Zero out of 23 pharmaceutical brands achieved brand name usage in AI-generated responses. Every major AI model defaults to INN or drug class terminology, regardless of how well-known the brand is.
This article presents the full data, explains the structural reasons behind it, and lays out the strategic pivot pharma marketers must make to regain visibility in AI-generated answers.
What the Data Reveals: 0% Brand Name Usage Across Every AI Model
Pharma brand AI visibility is not a nuanced problem with varying degrees of severity. The data is unambiguous.
PharmaGEO analyzed how three leading AI platforms — ChatGPT by OpenAI, Google Gemini, and Perplexity — represent 23 pharmaceutical brands when responding to health-related queries. The metric was straightforward: does the AI use the brand name, the INN (generic name), or the drug class when referencing the product?
Brand Name Recognition Results
| Metric | Result |
|---|---|
| Total brands analyzed | 23 |
| AI models tested | ChatGPT, Gemini, Perplexity |
| Brand name usage rate | 0% across all brands and all models |
| INN usage rate | Primary identifier in majority of responses |
| Drug class usage rate | Secondary fallback across all models |
Not a single brand, across any AI model, was referenced by its commercial name in AI-generated answers. The pattern held for blockbuster biologics, specialty drugs, and consumer-facing healthcare brands alike.
INN Recognition: How AI Actually Refers to Your Products
When AI models do recognize a pharmaceutical product, they overwhelmingly use the INN. Here is a sample of the recognition patterns observed:
| Brand Name | INN (Generic) | INN Recognition Rate | Drug Class Rate |
|---|---|---|---|
| Entyvio | vedolizumab | 67% | 33% |
| Imfinzi | durvalumab | 67% | 33% |
| Aristada | aripiprazole lauroxil | 67% | 33% |
| Parodontax | (consumer brand) | 0% | 67% |
| Ledaga | chlormethine | 33% | 67% |
| Beyfortus | nirsevimab | 67% | 33% |
Key Takeaway: INN recognition rates of 67% for products like Entyvio, Imfinzi, and Aristada confirm that AI models know these drugs exist. They simply refuse to call them by their brand names.
The Perplexity Problem: When AI Cannot Find You at All
Among the three platforms, Perplexity presented an additional challenge for pharma brand AI visibility. Unlike ChatGPT and Gemini, which at least reference products by their INN, Perplexity frequently returned "Not Found" results — failing to mention the product entirely.
This means the funnel is even more broken than the 0% brand name figure suggests. For certain products, the AI does not just strip the brand identity. It erases the product from the conversation altogether.
AI Visibility Does Not Equal Brand Recognition
One of the most counterintuitive findings is that high AI visibility scores do not translate into brand name usage. This distinction is critical for pharma marketers who may be measuring the wrong metric.
Beyfortus (nirsevimab) achieved 100% AI visibility, meaning all three AI models acknowledged the product's existence and included it in relevant therapeutic discussions. Yet brand name usage remained at 0%. Every reference used the INN "nirsevimab" or a class-level descriptor.
| Brand | AI Visibility Score | Brand Name Usage |
|---|---|---|
| Beyfortus | 100% | 0% |
| Entyvio | High | 0% |
| Imfinzi | High | 0% |
| Skyrizi | High | 0% |
Key Takeaway: Beyfortus proves that even 100% AI visibility does not produce brand name usage. Pharma needs a separate strategy for brand recognition in AI answers, distinct from general AI visibility tactics.
Every Rx Product Framed as an "Alternative"
The recognition crisis extends beyond naming conventions into therapeutic positioning. PharmaGEO analysis found that every prescription product is framed as an "Alternative" in AI-generated responses. No AI model positioned any Rx brand as a first-choice therapy.
The sole exception was Parodontax, a consumer oral care brand positioned for caries prevention, which occasionally received first-choice framing. For every other product in the dataset, AI models presented the drug as one option among several — never as the recommended or preferred treatment.
Why AI Models Default to INN: The Structural Causes
Understanding why AI models never use brand names is essential to building an effective pharmaceutical GEO strategy. The causes are structural, not incidental, and they will not resolve on their own.
Training Data Is Dominated by Scientific Literature
Large language models are trained on vast corpora that skew heavily toward scientific and regulatory sources. PubMed abstracts, clinical trial databases (ClinicalTrials.gov), WHO publications, Cochrane reviews, and FDA/EMA regulatory documents all use INNs as the standard identifier. The brand name appears in these sources only as a parenthetical, if at all.
WHO INN Conventions Shape Global Health Language
The World Health Organization's INN system was specifically designed to create a universal, nonproprietary naming convention for pharmaceutical substances. This system has been adopted as the default in virtually every scientific, regulatory, and clinical context worldwide.
Regulatory and Safety Framing Limits Brand Advocacy
AI models are also trained to avoid what could be perceived as product endorsement. Regulatory frameworks around pharmaceutical promotion, combined with the models' built-in safety guidelines, create a structural bias toward neutral, generic terminology.
Trending Queries Use Brand Names, but AI Answers Do Not
Perhaps the most striking disconnect: users search using brand names, but AI responds using INNs. Trending health queries include phrases like "Skyrizi vs Entyvio" and "is Imfinzi effective for lung cancer." The user is thinking in brand terms. The AI answers in generic terms.
Key Takeaway: AI models default to INNs because their training data, safety guidelines, and the WHO naming system all privilege generic names over brand names. This is a structural issue, not a bug to be fixed.
The INN-First Content Strategy: 7 Tactics to Reclaim Pharma Brand AI Visibility
The data demands a strategic pivot. Pharmaceutical organizations must adopt the INN-First Content Strategy — a framework that works with the structural biases of AI models rather than against them.
Lead with the INN, Anchor to the Brand
Every piece of digital content should lead with the INN and immediately establish the brand name in a reinforced pairing. Instead of "Entyvio is indicated for..." write "Vedolizumab (Entyvio) is indicated for..." This trains AI models to associate the INN with the brand, increasing the probability of co-occurrence in AI-generated responses.
Optimize for AI-Extractable Answer Paragraphs
AI models extract concise, self-contained statements. Structure your content so that the first sentence of every section directly answers a question. These "answer paragraphs" should contain both the INN and the brand name in a factual, non-promotional format that AI models can surface verbatim.
Build Structured Data Around the INN-Brand Pair
Implement schema markup (MedicalEntity, Drug, MedicalCondition) on all product pages that explicitly links the INN to the brand name. Structured data gives AI models a machine-readable signal that these two terms refer to the same entity.
Create Comparison Content That Mirrors Trending Queries
Since users search for "Skyrizi vs Entyvio" but AI answers with INNs, create authoritative comparison content that uses both naming conventions. Pages optimized for "risankizumab (Skyrizi) vs vedolizumab (Entyvio)" give AI models a source that bridges the gap between user intent and AI output.
Publish INN-Indexed Scientific Content at Scale
Supplement brand-focused content with INN-indexed scientific resources: mechanism-of-action explainers, therapeutic class overviews, and evidence summaries that use the INN as the primary keyword while maintaining brand association. This aligns with the sources AI models already trust.
Monitor AI Representation Continuously
Deploy a platform like PharmaGEO to track how AI models represent your products over time. AI model behavior changes with retraining cycles. What works today may not work in six months. Continuous monitoring allows you to detect shifts in visibility, recognition, and positioning before they affect commercial outcomes.
Align Cross-Functional Teams Around AI Visibility Metrics
Brand teams, medical affairs, digital, and market access must share a common understanding of AI visibility and recognition metrics. Establish pharma brand AI visibility as a KPI alongside traditional brand tracking metrics. If it is not measured, it will not be managed.
Key Takeaway: The INN-First Content Strategy does not abandon brand building. It adapts brand-building tactics to the reality of how AI models process and present pharmaceutical information.
Frequently Asked Questions
Why do AI models use generic drug names instead of brand names?
AI models use generic names (INNs) because their training data is dominated by scientific literature, regulatory documents, and clinical databases that use INNs as the standard identifier. The WHO INN system, PubMed, ClinicalTrials.gov, and FDA filings all default to nonproprietary names. AI models learn from these sources and replicate their naming conventions. Additionally, AI safety guidelines discourage what could be perceived as product endorsement, further reducing brand name usage.
Do any pharmaceutical brands achieve brand name recognition in AI search?
Based on PharmaGEO analysis of 23 pharmaceutical brands across ChatGPT, Gemini, and Perplexity, no brand achieved brand name usage in AI-generated responses. The 0% brand recognition rate was consistent across all product types, therapeutic areas, and AI platforms tested. Even brands with 100% AI visibility — such as Beyfortus — were referenced exclusively by their INN.
What is the difference between AI visibility and AI brand recognition for pharma?
AI visibility measures whether an AI model acknowledges your product when responding to relevant queries. AI brand recognition measures whether the AI uses your brand name when referencing that product. A product can have high visibility (the AI knows it exists) while having zero brand recognition (the AI only uses the INN or drug class name). PharmaGEO data shows these are independent metrics that require separate optimization strategies.
How does poor AI brand recognition affect pharmaceutical sales?
When AI models present every product by its generic name and frame it as one "alternative" among many, the competitive differentiation built through branding, clinical positioning, and KOL engagement is neutralized. As patients and HCPs increasingly rely on AI for health information, the inability of AI to distinguish branded products from their generic equivalents will erode prescribing preference, brand loyalty, and ultimately market share.
How can pharma companies track their brand visibility in AI models?
Pharma companies can use specialized platforms like PharmaGEO to monitor how AI models represent their products across ChatGPT, Gemini, Perplexity, and other generative AI tools. These platforms track visibility (whether the product appears), recognition (whether the brand name is used), positioning (whether it is framed as first-choice or alternative), and sentiment. Continuous monitoring is essential because AI model behavior changes with each retraining cycle.
The Brands That Adapt First Will Own the AI Channel
The 0% brand recognition rate is not a temporary glitch. It is the structural default of how AI processes pharmaceutical information. The training data, the naming conventions, and the safety guidelines of major AI platforms all converge on the same outcome: your brand name disappears.
But this is not a problem without a solution. The organizations that understand the mechanics of pharma brand AI visibility and adapt their content, data, and measurement strategies accordingly will gain a durable competitive advantage as AI becomes the dominant channel for health information.
The window to act is now. AI models are retrained on new data regularly. Content published today shapes the AI responses of tomorrow. Every quarter spent without an AI visibility strategy is a quarter where your brand falls further behind in the channel that is replacing traditional search.
PharmaGEO provides the data, benchmarks, and strategic framework to close the gap between where your brand stands in AI today and where it needs to be. The first step is measurement. The second step is action.
See how your brand appears in AI answers.
Get a cross-LLM reputation report in minutes. No patient data. EU-based storage.
Data source: PharmaGEO platform analysis of 23 pharmaceutical brands across OpenAI, Gemini, and Perplexity (2025)